Compounds > sulfatroxazole
Page last updated: 2024-12-06

sulfatroxazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfatroxazole is a sulfonamide antibiotic that was once widely used for the treatment of bacterial infections, but its use has declined due to the emergence of resistance. It is a synthetic compound that works by inhibiting the synthesis of dihydrofolic acid, an essential precursor for the synthesis of purines and nucleic acids in bacteria. Sulfatroxazole is typically administered orally and is well absorbed from the gastrointestinal tract. It is metabolized in the liver and excreted in the urine. Sulfatroxazole is effective against a wide range of gram-positive and gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli. However, it has limited activity against Pseudomonas aeruginosa and other resistant organisms. Sulfatroxazole is still used for the treatment of certain infections, such as urinary tract infections and otitis media, but it is often used in combination with other antibiotics to improve efficacy. It is also used to prevent infections in people who are at risk, such as those who have had surgery or have a weakened immune system. Sulfatroxazole is available in a variety of formulations, including tablets, capsules, suspensions, and intravenous solutions. Sulfatroxazole is generally well tolerated, but it can cause side effects such as nausea, vomiting, diarrhea, and allergic reactions. In some cases, it can also cause more serious side effects such as liver damage, blood disorders, and Stevens-Johnson syndrome. Sulfatroxazole is not recommended for use in pregnant women or breastfeeding mothers. '
```

sulfatroxazole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID31771
CHEMBL ID26630
SCHEMBL ID93862
MeSH IDM0139178

Synonyms (28)

Synonym
bdbm50034433
4-amino-n-(4,5-dimethyl-isoxazol-3-yl)-benzenesulfonamide
CHEMBL26630 ,
sulfatroxazole
4-amino-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
n1-(4,5-dimethyl-3-isoxazolyl)sulfanilamide
n1-(4,5-dimethyl-3-isoxazolyl)sulfanilamid
unii-zxc0pt8ffs
sulfatroxazol [inn-spanish]
23256-23-7
sulfatroxazolum [inn-latin]
einecs 245-530-5
sulfatroxazolum
sulfatroxazol
n(sup 1)-(4,5-dimethyl-3-isoxazolyl)sulfanilamide
sulfatroxazole [inn:ban]
zxc0pt8ffs ,
SCHEMBL93862
sulfatroxazole [mart.]
sulfatroxazole [inn]
DTXSID20177829
BCP24928
4,5-dimethyl-3-sulfanilamidoisoxazole; isosulfafurazole; n1-(4,5-dimethyl-3-isoxazolyl)sulfanilamide
Q27295939
AT25048
YAA25623
4-amino-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzene-1-sulfonamide
n1-(4,5-imethyl-3-isoxazolyl)sulfanilamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"5 h) and the bioavailability was only 12."( Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model.
Maas, R; Rátz, V; Semjén, G; van Miert, AS; Witkamp, RF, 1995)		0.29

Dosage Studied

ExcerptRelevanceReference
" Thirty -six pigs were treated with trimethoprim/sulfatroxazole IM in the nec k at a dosage of 16 mg/kg body weight for five days."( [Study of the elimination of residues and local tissue injury following intramuscular injection of a solution of the combination trimethoprim/sulfatroxazole in pigs].
Edwards, HJ; Kissmeyer, AM; Pott, JM; Skov, B; Szancer, J, 1996)		0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Endothelin-1 receptorRattus norvegicus (Norway rat)IC50 (µMol)2.63000.00001.774610.0000AID66057; AID66184
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID66184Displacement of [125 I] ET-1 from rat aortic smooth muscle A7r5 cells transfected with Endothelin A receptor2000Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16
Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
AID66057Antagonism of [125 I]ET-1 binding to the rat endothelin receptor in vascular smooth muscle VSM-A10 cells.1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
AID180489Tested for antagonistic activity against ET-1 induced increase in intracellular [Ca2+] in VSM-A10 cells.1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Discovery and structure-activity relationships of sulfonamide ETA-selective antagonists.
AID66201Inhibition of [125I]endothelin-l binding to endothelin A receptor of rat thoracic aorta smooth muscle cells1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Three-dimensional quantitative structure-activity relationships of sulfonamide endothelin inhibitors.
AID66699Binding affinity towards displacement of [125 I] ET-3 from COS-7 cells transfected with porcine Endothelin B receptor.2000Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16
Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
AID493017Wombat Data for BeliefDocking2000Bioorganic & medicinal chemistry letters, Aug-21, Volume: 10, Issue:16
Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (54.55)18.7374
1990's4 (36.36)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
sulfamerazine
[no description available]		1.9810pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		8.77110isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfathiazole
Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.		1.98101,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic
sulfisoxazole
Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.		2.6830isoxazoles;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
drug allergen
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		6.9910aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		1.9910penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide
5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide: structure in first source; endothelin receptor antagonist		2.3920naphthalenes;
sulfonic acid derivative
n(4)-acetylsulfisoxazole
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials